Drug intelligence / Profile preview

NNC0638-0355

Development stage: Phase 1
Lead developer: Novo Nordisk
Modality: Peptides, Small Molecules
Administration: Subcutaneous

Overview

NNC0638-0355 is a once-weekly subcutaneous synthetic peptide and amylin analogue developed by Novo Nordisk for the treatment of obesity and overweight. It acts as an agonist of the amylin receptor (AMYR), aiming to mimic or enhance the physiological effects of endogenous amylin, which plays a role in regulating appetite and food intake. The drug is currently in Phase 1 clinical trials to assess its safety, tolerability, pharmacokinetics, and potential efficacy in people with overweight or obesity. As of October 2024, it has not been approved for prescription use[1][2][3][4][7].

Targets

AMY receptor (Calcitonin receptor (with ramps))

Beyond the preview

Go deeper on NNC0638-0355.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on NNC0638-0355.

Explore the full profile